Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs). This class of drugs also includes several competitors to Xaretlo, including Eliquis, Pradaxa, and Savaysa, which is the newest class member. These medications are approved by the U.S. Food and Drug Administration (FDA), to treat two serious medical conditions, but there are other approvals in the pipeline as we will discuss in this blog post.
The first, and most common medical condition treatable by Xarelto (according to their marketing) is a serious condition known as atrial fibrillation (Afib). Afib, as you may have heard Saturday Night Live alum or legendary golfer Arnold Palmer tell you on the seemingly nonstop barrage of Xarelto commercials, is an irregular heartbeat not caused by a heart valve defect. This medical condition can cause blood clots to form in a patient, and these clots can travel though the circulatory system and into the lungs. If they enter the lungs, they can puncture the tissue causing the lungs to fill with blood. This is an often-deadly complication of the clotting disorder known as a pulmonary embolism, or PE as it often called. The clots can also reach the brain, where they can block the flow of oxygen-rich blood, which can cause a stroke. Continue reading